Sitagliptin is the first dipeptidyl peptidase-IV (DPP-IV) inhibitor medicine, which is widely used in the treatment of type 2 diabetes. Using in vitro biosynthetic technique, Abiochem has developed the enzyme catalyst and mass production process for Sitagliptin with independent intellectual property rights. This biosynthetic enzyme can be re-utilized for tens of times under room temperature and pressure. It generates less industrial wastes with reduced energy consumption, and has significant advantage in the cost of production.

Dolutegravir is a highly potent orally administrated HIV integrase inhibitor, which is widely used in the treatment of AIDS. Based on its core platforms such as “Intelligent Design”, “Enzyme Engineering”, “Bioreaction Engineering” and “Material Synthesis”, Abiochem has developed the technique for the biosynthesis and mass production process of Dolutegravir with independent intellectual property rights. This technique has significant advantage with a simplified operation process, less industrial wastes, reduced energy consumption and carbon emission, which greatly lowered production cost making it very competitive within the industry.